AICRO
Associazione Italiana Contract Research Organization

April, 2024

AICRO Mission Summary Document 2024-2026

Dear Colleagues,

we share the strategic guidelines established by the Executive Boardfor the Association in this three-year period '24-'26.

- We will continue to pursue the objective of safeguarding our ability to operate effectively and efficiently. In this area, the main focus is **on overcoming the outdated obligations laid down in Ministerial Decree 15/11/11.** We will also interact with the Garante Privacy and other Authorities **to represent the limitations arising from the transposition of the GDPR in Italy** (Decree 101 of 10/8/18) with the intention of obtaining that the GDPR has the same application in Italy as in the other Member States. We will work possibly in agreement with the institutions and with the support of other interested parties we will continue to seek a dialogue aimed at removing these barriers.
- We want to be involved and play a leading role in the evolution of clinical research by providing our contribution of knowledge and experience on the **most topical issues** such as the implementation of **EU CTRs,** guidelines for the use of **computerised systems**, the conduct of **decentralised trials (DCT),** the use of **telemedicine**, also with new and original contributions that can be generated in the CRO world.
- We will continue to increase our role as an authoritative and reliable interlocutor in clinical research by interacting with all interested parties (institutions, scientific societies and other organisations) and by actively and continuously participating in all **public forums** that can help spread our thinking.
- **Education and information** is at the core of our work to achieve a healthy, competitive and aware system. In this regard, we will work to expand our MyCROscope initiative and continue to collaborate with academia on research and education initiatives. In this field, too, we will have to be proactive and place great emphasis on the possibility of sharing not only training in a formal manner but also experiences, albeit sometimes imperfect ones.
- **The growth** of the Association remains a crucial point. We will work to plan the entry of new **members among all the Service Providers** and increase our visibility vis-à-vis the labour market, scientific societies, trial centres and patient associations. We will contribute to defining the scientific, social and economic valorisation of clinical trials in Italy.
- The Association promotes the professional quality of its members and the relevance of the **national clinical research system in the European and international context**, so as to strengthen collaboration relations with CROs in other countries and institutional representation and towards all stakeholders, with the awareness that the presence of Italian representatives at international tables can contribute to innovating and strengthening the national system.
- The Executive Board remains open to **collecting and discussing requests from members**. We also call for the active participation of an increasing number of colleagues in the working groups. We will continue with initiatives **to communicate** everything we do externally, both through social channels and through events and publications.

We are confident that these guidelines can be shared by the Associates.